With Specialty Pharmaceuticals representing half of U.S. Pharmaceutical Spend, self-funded plans need to be aware and concerned with the cost and financial impact of these medications in the pipeline. Please join Andy Reeves RPH CEO of Optimed in an informative discussion regarding today’s Specialty Pharmaceutical Market, the forces creating this trend of increasing utilization and costs, therapies and battle-tested strategies to mitigate and combat these market forces.